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Summary
Most types of normal cells require integrin-mediated attachment to extracellular matrix to be able to
respond to growth factor stimulation for proliferation and survival. Therefore, a consensus that integrins
are close collaborators with growth factors in signal transduction has gradually emerged. Some integrins
and growth factor receptors appear to be normally in relatively close proximity, which can be induced to
form complexes upon cell adhesion or growth factor stimulation. Moreover, since integrins and growth
factor receptors share many common elements in their signaling pathways, it is clear tzhat there are many
opportunities for integrin signals to modulate growth factor signals and vice versa. Increasing evidence
indicates that integrins can crosstalk with receptor tyrosine kinases in a cell- and integrin-type-dependent
manner through a variety of speciﬁc mechanisms. This review is intended speciﬁcally for summarizing
recent progress uncovering how the hepatocyte growth factor receptor c-Met coordinates with integrins to
transmit signals.
Introduction
Cell adhesion to extracellular matrix (ECM) is a
prerequisite for cell proliferation and survival [1].
The eﬀects of ECM on cells are mainly mediated
by the integrins, a large family of cell surface
receptors that bind to ECM components, organize
the cytoskeleton, and activate intracellular signal-
ing pathways. Each integrin is composed of two
subunits: a and b. In mammals, 18 a and 8 b
subunits associate in various combinations to form
24 integrins that can bind to distinct, although
partially overlapping, subsets of ECM proteins [2,
3]. Several lines of evidence indicate that pathways
for integrin signaling and growth factor signaling
are mechanistically linked. First, cell adhesion to
ECM is required for cells to respond to certain
growth factors [1]. Second, integrin-mediated cell
adhesion and motility can be modulated by growth
factors [4–6]. Third, many of the signaling mole-
cules associated with growth factor receptors, such
as Src, are also present in integrin complexes at
focal adhesions [7]. Actually, many previous stud-
ies suggested that integrins can crosstalk with
receptor tyrosine kinases in a cell- and integrin-
type-dependent manner through a variety of spe-
ciﬁc mechanisms [8, 9].
Most integrins activate focal adhesion kinase
(FAK) which transduces signals to the down-
stream through its interaction with several intra-
cellular signaling molecules, including the Src
family kinases, PI3K, phospholipase C-c1, Grb2,
p130Cas, and paxillin [10, 11]. FAK is well known
for its pivotal role in the control of integrin-
mediated cell functions, including cell migration,
cell cycle progression, and cell survival. However,
increasing evidence has also suggested that FAK
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may be a point of convergence of integrin and
growth factor signaling pathways. In addition to
cell adhesion, a number of growth factors were
shown to stimulate the tyrosine phosphorylation
of FAK [12–14] through activation of the Src
family kinases [14] and/or physical association of
FAK with the growth factor receptors [15]. The
phosphorylation and activation of FAK in re-
sponse to growth factor stimulation facilitate its
association with other signaling molecules, thereby
leading to ampliﬁcation of downstream signals [14,
15].
Hepatocyte growth factor (HGF), also known
as scatter factor, is a mesenchymally derived factor
that elicits multiple cellular responses, including
proliferation, migration, and morphogenesis, on
various types of cells, [16–18]. The diverse biolog-
ical eﬀects of HGF are transmitted through
activation of its transmembrane receptor encoded
by the c-met proto-oncogene [19]. The Met recep-
tor is a heterodimer composed of a 45-kDa a chain
that remains entirely extracellular, and a 145-kDa
b chain that traverses the plasma membrane and
contains the intracellular tyrosine kinase domain
[20, 21]. Upon HGF binding, the intrinsic tyrosine
kinase of the receptor is activated resulting in
autophosphorylation on speciﬁc tyrosine residues
in the b chain [22, 23]. Two tyrosine residues in the
COOH-terminus of the b chain (Tyr-1349 and
Tyr-1356) are required for all biological activities
of the receptor [24, 25] and serve as docking sites
for the Grb2-associated binder-1 (Gab1) docking
protein [26, 27] and multiple Src homology 2 and
phosphotyrosine binding domain-containing pro-
teins [28, 29]. In human cancers, the c-met gene has
frequently been found to be ampliﬁed, mutated or
overexpressed [17, 18].
Recent studies indicated that HGF signaling
can crosstalk with integrin signaling through at
least three modes. First, the Met receptor physi-
cally associates with integrins at the plasma
membrane where they reciprocally regulate each
other. Second, HGF and integrin signaling path-
ways are converged to some intracellular signaling
molecules, such as FAK and Src, which further
transduce signals to the downstream. Thirdly,
HGF signaling leads to alteration in the expression
of integrins that is essential for the biological
activities of HGF.
Met-integrin interplay at the plasma membrane
The HGF receptor c-Met engages in reciprocal
regulation with integrins at the plasma membrane
(Figure 1). The a6b4 integrin has been shown to
cooperate with the function of HGF and its
receptor c-Met in carcinoma cells, resulting in
enhanced invasive growth [30]. Upon c-Met acti-
vation, a6b4 integrin physically associates with
Figure 1. c-Met and integrin interplay at the plasma membrane. (a) In response to HGF stimulation, a6b4 integrin physically asso-
ciates with c-Met and undergoes tyrosine phosphorylation on the b4 cytoplasmic domain, which subsequently forms a complex
with Shc and PI3K, thereby potentiating Ras and PI3K signaling. The interaction of the b4 cytoplasmic domain with the adaptor
protein Shc is required for HGF-induced invasion of cancer cells. (b) Ligand-independent activation of c-Met by cell adhesion.
However, integrin speciﬁcity and the mechanism responsible for this form of c-Met activation remain unclear.
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c-Met and undergoes tyrosine phosphorylation on
the b4 cytoplasmic domain, which subsequently
forms a complex with Shc and PI3K, thereby
potentiating Ras and PI3K signaling (Figure 1a).
The a6b4 integrin is somewhat special among
other integrins in that the b4 subunit contains an
unusually long cytoplasmic domain, which pro-
vides this integrin with additional Shc binding sites
to the Met- a6b4 receptor complex, thereby
amplifying Met signaling above a critical threshold
for invasive behavior. The extracellular domain of
the b4 integrin is not required for its cooperation
with the activated c-Met, suggesting an adhesion-
independent role for this integrin. In addition, the
a6b4 integrin also associates with the epidermal
growth factor (EGF) receptor family member
ErbB2 in carcinoma cells [31]. Again, the b4
cytoplasmic domain as a monomer is necessary
and suﬃcient to associate with ErbB2, whereas the
extracellular domain, and hence matrix binding, is
not required for this function [32].
Integrins, on the other hand, can induce
various growth factor receptors to undergo
ligand-independent activation, at least to the
extent of enhanced tyrosine phosphorylation after
cell adhesion [33–37]. It has been shown that the
majority of c-Met in certain tumor cells can be
activated by cell attachment, presumably through
integrins, in the complete absence of HGF [34]
(Figure 1b). Overexpression of c-Met appears to
be a prerequisite for its activation by cell adhesion.
Neither the integrity of the actin cytoskeleton nor
FAK activation is required for this form of c-Met
activation [34]. Moreover, overexpression of c-Met
in hepatocytes of mice enables ligand-independent
activation of the receptor that leads to hepatocel-
lular carcinoma [38]. However, integrin speciﬁcity
and the mechanism responsible for the ligand-
independent activation of c-Met remain unclear. A
previous study done by Moro et al. [39] provides a
possible explanation for how integrin-mediated
adhesion could induce phosphorylation of growth
factor receptors. They found that upon cell adhe-
sion, avb3 and b1 integrins associate with EGF
receptors in a complex with p130Cas and c-Src,
both of which are crucial for integrin-induced
phosphorylation of EGF receptors. Notably, the
pattern of EGF receptor phosphorylation induced
by integrins is unique, compared to the pattern
after EGF-induced autophosphorylation. They
found that tyrosine 1148 is unphosphorylated, a
key residue that is normally phosphorylated after
EGF stimulation. However, four other tyrosines
are phosphorylated normally [39].
Intracellular signaling, called ‘‘inside-out’’ sig-
naling, controls the interaction between integrins
and ligands [5, 6]. This cell type-speciﬁc process
modulates integrin aﬃnity, which is caused by a
conformational change and modulation of lateral
diﬀusion and/or integrin clustering. HGF has
been shown to activate integrin avb3 in epithelial
cells [40], avb3 and a5b1 in endothelial cells [41],
LFA-1 (aM b2) in colon cancer cells and neu-
trophils [42, 43], and a4b1 in B cells [44, 45]. In
contrast, HGF was reported to inhibit aIIbb3
activation in platelet cells [46]. Nevertheless, the
mechanisms underlying those phenomena are
unclear.
FAK serves as a point of convergence of HGF
and integrin signaling pathways in the cytoplasm
Although a number of growth factors are known
to modulate cell motility, HGF is unique because
of the intensity with which it stimulates cell
motility and induces epithelial–mesenchymal tran-
sition. Since FAK is well known for its pivotal role
in regulating integrin-mediated cell motility [11], it
was reasonable to speculate that FAK is involved
in HGF signaling and plays a role in HGF-
stimulated cell motility. It is now known that HGF
rapidly induces an increase in FAK phosphoryla-
tion through at least two mechanisms: one is
indirectly mediated by Src [14] and the other is
directly phosphorylated by c-Met (Figure 2a). The
maximal activation of FAK upon HGF stimula-
tion may be reached only when both Met–FAK
and Met–Src–FAK pathways are activated. The
activated FAK functions as a signaling platform to
potentiate HGF-elicited signals, thereby contrib-
uting to HGF-stimulated cell motility [47] and cell
invasion [48]. In accordance with the observation
that increased level of FAK contributes to a more
aggressive phenotype in tumors [49–51], overex-
pression of FAK renders cultured epithelial cells
susceptible to cellular transformation by HGF
stimulation [48]. Recently, we found that FAK
directly interacts with phosphorylated c-Met upon
HGF stimulation. Under certain circumstances,
for example, when c-Met is overexpressed and/or
constitutively activated, Met–FAK interaction
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could become constitutive independently of HGF
stimulation. This interaction occurs through the
band 4.1 and ezrin/radixin/moesin homology
domain (FERM domain) of FAK and the phos-
phorylated Tyr-1349 and Tyr-1356 of c-Met.
Notably, the ability of FAK to promote HGF-
stimulated cell invasion largely depends on its
direct interaction with Met.
The immediate response of FAK to HGF
stimulation occurs in close proximity to c-Met as
described above, which is independent of integrin-
mediated cell adhesion [14]. Since HGF is known
to selectively increase the expression of certain
integrins such as integrin a2 and a3 [47, 52, 53], it
is plausible that increased levels of integrins may
further lead to the activation of FAK following
cell adhesion to ECM proteins. It is therefore likely
that the eﬀect of HGF on FAK activation can
be through an immediate (integrin-independent)
response and a delayed (integrin-dependent)
response (Figure 2b). The sustained activations
of FAK and other signaling molecules such as
ERK (see below) are critical for the long-term
cellular responses to HGF. For instance, the
scatter response of Madin–Darby canine kidney
(MDCK) cells to HGF stimulation is a dynamic
process usually initiated by membrane ruﬄing and
centrifugal spreading of cell colonies (after 1–3 h).
Subsequently, some cells within the colony begin
to detach from their neighboring cells (after 3–6 h)
and exhibit a shape resembling that of motile
ﬁbroblasts. These cells continue to migrate (from
6 h), ﬁnally leading to a ‘‘scatter’’ phenomenon
[47].
HGF induces the expression of integrins
via sustained activation of ERK
Although the role of ERK (extracellular signal-
regulated kinase) singling pathway in cell prolifer-
ation has been well established [54], increasing
Figure 2. FAK serves as a point of convergence of HGF and integrin signaling pathways in the cytoplasm. (a) HGF rapidly in-
duces an increase in FAK phosphorylation through at least two modes: Met–Src–FAK and Met–FAK pathways. The activated
FAK functions as a signaling platform to potentiate HGF-elicited signals, thereby contributing to HGF-stimulated cell motility
and cell invasion. Note that the ability of FAK to promote HGF-stimulated invasion largely relies on its direct interaction with
Met. (b) The eﬀect of HGF on FAK phosphorylation may be through an immediate (integrin-independent) response and a delayed
(integrin-dependent) response. The de novo expression of integrins induced by HGF may contribute to the delayed phase of FAK
phosphorylation.
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evidence suggests that the duration of ERK
activation may be a crucial determinant for cells
to proceed certain cellular functions other than
proliferation [55]. For example, in phaeochromo-
cytoma PC12 cells, sustained, but not transient,
activation of ERK precedes diﬀerentiation into
sympathetic-like neurons [56]. Likewise, HGF has
been reported to induce sustained activation of
ERK [52, 57–59]. In MDCK cells, sustained
activation (at least for 12 h) of ERK is required
for HGF to induce cell scattering [52, 58]. In
contrast, EGF induces transient activation of
ERK in MDCK cells, which declines by 30 min
and returns to the basal level by 1 h post stimu-
lation. Whereas HGF induces scatter response of
MDCK cells, EGF only induces lamellipodium
formation around the cell colony and fails to
trigger cell scattering (Figure 3a). The sustained
activation of ERK induced by HGF coincides with
its persistent nuclear accumulation, which results
in the expression of several genes such as integrins
a2 and a3 and matrix metalloproteinase-9 [52, 58].
The inductions of integrin a2b1 and metallopro-
teinase-9 are required for HGF-induced cell
scattering [52, 58]. In addition, the up-regulations
of integrins a2b1 and a3b1 are important for
HGF-induced branching tubulogenesis in three-
dimensional collagen gels [53, 60, 61].
The increased expression of integrin a2 by
HGF is a consequence of increased integrin a2
mRNA likely due to transcriptional activation
[52]. Characterization of the 5¢-ﬂanking region of
human integrin a2 gene reveals that the promoter
region contains consensus binding sites for several
transcription factors, including Sp1, AP1, and
AP2 [62]. The binding of phosphorylated Sp1 to
two Sp1 binding sites in the core promoter region
of human integrin a2 gene is required for full
promoter activity [63]. It is known that ERK
activation increases AP1 activity via c-Jun activa-
Figure 3. Sustained activation of ERK induced by HGF results in the expression of integrins. (a) In MDCK cells, sustained activa-
tion of ERK and its persistent nuclear retention lead to expression of several genes such as integrins. The induction of a2 b1 inte-
grins is essential for HGF to induce cell scattering and tubulogenesis. For the same type of cells, EGF induces transient activation
of ERK and fails to induce such cellular responses. (b) A proposed model for HGF to induce sustained activation of ERK and its
persistent retention in the nucleus. Evidence suggests that FAK and Gab1 may function as a platform to amplify signals, leading
to sustained ERK activation. In the case of Gab1, its prolonged phosphorylation and association with the tyrosine phosphatase
SHP-2 are essential for sustained activation of ERK. Active ERKs translocate to the nucleus where they phosphorylate immediate
early gene products such as Sp1, Elk, and c-Fos. Carboxy-terminal phosphorylation stabilizes c-Fos and primes additional phos-
phorylation by exposing a binding site for ERK, termed the DEF domain. Binding of ERK to the DEF domains of c-Fos and/or
other immediate early gene products may cause accumulation of ERK in the nucleus, thereby leading to the expression of target
genes.
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tion and increased c-Fos synthesis, leading to an
increase in c-Jun/c-Fos heterodimerization and
DNA binding [64, 65]. In addition, ERK can
phosphorylate Sp1 and induce its DNA binding
activity [66]. Therefore, it is possible that persistent
nuclear accumulation of ERK induced by HGF
stimulation may target Sp1 and AP1, leading to
activation of integrin a2 gene.
The mechanism by which HGF induces sus-
tained activation of ERK and its persistent nuclear
retention is unclear. Since integrin-mediated cell
adhesion to ECM proteins activates the ERK
signaling pathway and often potentiates the eﬀect
of growth factors on activating the pathway [67],
the de novo expression of integrins induced by HGF
may contribute to the sustained phase of ERK
activation (Figure 3b). It was proposed that pro-
longed phosphorylation of the major Met-docking
protein Gab1 and its association with the tyrosine
phosphatase SHP-2 are required for sustained
activation of ERK and for epithelial morphogen-
esis downstream from c-Met [59]. Overexpression
of FAK and, presumably, its interaction with Met
potentiates the duration of ERK activation [48].
Moreover, York et al. [56] showed that in PC12
cells, the early phase of nerve growth factor-
stimulated ERK activation is mediated by the
small GTPase Ras, but the sustained phase of the
ERK activation is due to activation of another
small GTPase, Rap1. The role of Rap1 in HGF-
induced sustained activation of ERK remains to be
clariﬁed. It was reported that the immediate early
gene product c-Fos functions as a sensor for ERK
signal duration [68]. When ERK activation is
transient, its activity declines before the c-Fos
protein accumulates, and under such condition
c-Fos is unstable. However, when ERK signaling
is sustained, it persistently accumulates in
the nucleus and phosphorylates c-Fos. Carboxy-
terminal phosphorylation stabilizes c-Fos and
primes additional phosphorylation by exposing a
binding site for ERK, termed the DEF domain.
Interestingly, putative DEF domains are also
found in other AP-1 proteins, such as Fra-1,
Fra-2, JunB, and JunD [68]. It has been shown
that HGF induces increased and prolonged
expression of c-Fos [58]. It remains to be
determined whether the interaction of ERK with
c-Fos or other DEF domain-containing proteins
in the nucleus is essential for its persistent
nuclear retention.
Perspectives
There has been substantial recent progress in
understanding how integrin and the c-Met recep-
tor collaborate to transmit signals and thereby
coordinate regulate cell behavior. The picture
emerging from these studies is that the crosstalk
networks between signaling pathways from both
types of cell surface receptors are intertwined at
various cellular locations through various modes.
Nonetheless, several open questions remain to be
answered. At the plasma membrane, it will be
important to determine which types of integrins
are involved in ligand-independent activation of
c-Met and the underlying mechanism for the
activation. In the cytoplasm, some molecules, e.g.
FAK, are engaged in both integrin and HGF
signaling pathways. Does integrin compete with
c-Met for FAK? Do signals propagated by
reciprocal regulation between Met and FAK
produce unique biological eﬀects? In the nucleus,
it will be important to determine the mechanism by
which HGF induces persistent nuclear retention of
ERK.What are the targets of transient vs. sustained
activation of ERK? Understanding these circuits in
detail should shed light on a variety of pathological
states as well as delineate more eﬀective strategies
for future therapeutic intervention.
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